Concepedia

Daniel Ries

DR

Statistics

Publications

7

Citations

120

H-Index

7

Active since

2015

Affiliations

Orlando Clinical Research Center(Current)

Sandia National Laboratories

Prism Clinical Research

Iowa State University

Daniel Ries is an author at Orlando Clinical Research Center specializing in pharmacokinetics in renal impairment, pharmacokinetics in kidney disease, and pharmacology.

ORCID

Publications per year

2015–2024

7

Publications

7

Pharmacokinetics of bempedoic acid in patients with renal impairment

Benny Amore, William J. Sasiela, Daniel Ries et al. · Clinical and Translational Science · 2021 · 34 citations · Full text

, , +16

P0712 : The pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment

Erik Mogalian, Anita Mathias, Diana M. Brainard et al. · Journal of Hepatology · 2015 · 18 citations

, , +13

Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease

Detlef Albrecht, Mintu P. Turakhia, Daniel Ries et al. · Thrombosis and Haemostasis · 2017 · 17 citations

, , +12

NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients

S Maruyama, Thomas Marbury, Jeffrey J. Connaire et al. · Kidney International Reports · 2020 · 14 citations · Full text

, , +17

Commercial Devices Provide Estimates of Energy Balance with Varying Degrees of Validity in Free-Living Adults

Robin P. Shook, Hung‐Wen Yeh, Gregory J. Welk et al. · Journal of Nutrition · 2021 · 14 citations

, , +10

1–5 of 7